These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17925571)

  • 1. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
    Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
    J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
    [No Abstract]   [Full Text] [Related]  

  • 2. Erlotinib induced skin rash spares skin in previous radiotherapy field.
    Mitra SS; Simcock R
    J Clin Oncol; 2006 Jun; 24(16):e28-9. PubMed ID: 16735697
    [No Abstract]   [Full Text] [Related]  

  • 3. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
    Benomar S; Boutayeb S; Afifi Y; Hamada S; Bouhllab J; Hassam B; Errihanni H
    Dermatol Online J; 2009 Nov; 15(11):2. PubMed ID: 19951638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
    Yalçin S; Dizdar O; Yalçin B; Gököz O
    J Am Acad Dermatol; 2008 Jan; 58(1):178-9. PubMed ID: 18158935
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosaceiform eruption induced by erlotinib.
    Patrizi A; Bianchi F; Neri I
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
    Acharya J; Lyon C; Bottomley DM
    J Am Acad Dermatol; 2009 Jan; 60(1):154-7. PubMed ID: 19103369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F; Cozzani E; Parodi A
    J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of bullous dermatitis induced by erlotinib.
    Oteri A; Cattaneo MT; Filipazzi V; Ferrario S; Gambaro A; Isabella L; Tosca N; Clementi E; Radice S; Piazza E
    Oncologist; 2009 Dec; 14(12):1201-4. PubMed ID: 19965913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
    Chiu HY; Cheng YP; Jee SH; Tsai TF
    Clin Exp Dermatol; 2012 Dec; 37(8):922-4. PubMed ID: 22731795
    [No Abstract]   [Full Text] [Related]  

  • 12. Erlotinib-induced pustular eruption.
    Cusano F; Ferrara G; Barletta E; Ingordo V
    G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib-induced rash spares previously irradiated skin.
    Lips IM; Koster ME; Houwing RH; Vonk EJ
    Strahlenther Onkol; 2011 Aug; 187(8):499-501. PubMed ID: 21789741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib-induced scalp perifolliculitis.
    Rallis E; Petronic-Rosic V; Korfitis C
    Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
    Lin TC; Wu PY
    Cutis; 2011 Dec; 88(6):281-3. PubMed ID: 22372166
    [No Abstract]   [Full Text] [Related]  

  • 17. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
    Vergou T; Stratigos AJ; Karapanagiotou EM; Matekovits AE; Dilana KD; Tsimboukis S; Antoniou C; Chasapi V; Syrigos KN
    J Am Acad Dermatol; 2010 Aug; 63(2):e56-8. PubMed ID: 20633793
    [No Abstract]   [Full Text] [Related]  

  • 18. Purpuric drug eruption and alopecia induced by erlotinib.
    Nakamura-Wakatsuki T; Yamamoto T
    Dermatol Online J; 2012 May; 18(5):16. PubMed ID: 22630586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib induced target-like purpura.
    Rungtrakulchai R; Rerknimitr P
    Dermatol Online J; 2014 Feb; 20(2):. PubMed ID: 24612572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
    Ong CK; Tan WC; Chan LC; Abdul Razak M
    Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.